Beam Therapeutics Inc.

BEAM

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001745999

C/D

on the C/D boundary of 370 graded peers in healthcare

rank 226 of 370; percentile 61.0; sampling error 2.5 points; lower is stronger


A B C D E

C/D, the tortoise




Scoreboard	
Profitability	E percentile 95.3
Solvency	A percentile 17.3
Growth and financing	B/C percentile 42.3
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.5B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 24, 2026 245 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026
Last close	$23.80 2026-10-26; market equity $2.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 95.3						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	20.5%	(6.6%)		95.3	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 17.3						
Twelve-month failure probability	0.03%	0.07%		24.0	247	2026-06-30
Altman Z double-prime	5.19	(0.33)		18.1	751	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	13.09x	2.94x		9.9	832	2025-12-31
Growth and financing, sleeve percentile 42.3						
Revenue growth, three-year compound	31.9%	10.1%		20.4	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	3.4%	2.1%		44.7	697	2025-12-31
Net share issuance, one year	21.7%	2.5%		61.8	634	2026-02-17

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
221	Trulieve Cannabis Corp. (TRLV)	59.6	C/D	fortress balance sheet
222	ARS Pharmaceuticals, Inc. (SPRY)	59.9	C/D	short runway
223	Labcorp Holdings Inc. (LH)	60.2	C/D	
224	GeneDx Holdings Corp. (WGS)	60.4	C/D	fortress balance sheet
225	Twist Bioscience Corp. (TWST)	60.7	C/D	fortress balance sheet
226	Beam Therapeutics Inc. (BEAM)	61.0	C/D	
227	Teva Pharmaceutical Industries Ltd. (TEVA)	61.2	C/D	
228	Akebia Therapeutics, Inc. (AKBA)	61.5	C/D	fortress balance sheet
229	Lenz Therapeutics, Inc. (LENZ)	61.8	C/D	short runway
230	Embecta Corp. (EMBC)	62.1	C/D	late filer
231	Strata Critical Medical, Inc. (SRTA)	62.3	C/D	short runway, fortress balance sheet

What the price implies

at the 2026-10-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	21.3%	7.7%	60
Distance from 52-week high	(37.3%)	(31.2%)	40
EBIT to enterprise value	(16.4%)	(1.5%)	26

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	(14.7%)	(1.0%)	27
Book value to price	0.43	0.28	64
Sales to price	0.06	0.30	18
Composite equity issuance, five years	50.4%	20.5%	66
Relative strength against the sector, log excess return	(0.02)	(0.14)	60

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$219.8M
Operating cash flow, four quarters	-$359.4M
Months of runway	7.3
Days since last periodic filing	84 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	$39.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$80.0M	2025-12-31	2026-02-24	10-K	26-065194
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$345.1M	2025-12-31	2026-02-24	10-K	26-065194
3	assets	us-gaap:Assets	$1.5B	2025-12-31	2026-02-24	10-K	26-065194
4	assets	us-gaap:Assets	$1.1B	2024-12-31	2026-02-24	10-K	26-065194
5	current assets	us-gaap:AssetsCurrent	$1.3B	2025-12-31	2026-02-24	10-K	26-065194
6	current liabilities	us-gaap:LiabilitiesCurrent	$96.9M	2025-12-31	2026-02-24	10-K	26-065194
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-02-24	10-K	26-065194
8	operating income	us-gaap:OperatingIncomeLoss	-$383.7M	2025-12-31	2026-02-24	10-K	26-065194
9	book equity	us-gaap:StockholdersEquity	$1.2B	2025-12-31	2026-02-24	10-K	26-065194
10	liabilities	us-gaap:Liabilities	$242.8M	2025-12-31	2026-02-24	10-K	26-065194
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$139.7M	2025-12-31	2026-02-24	10-K	26-065194
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$63.5M	2024-12-31	2026-02-24	10-K	26-065194
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$377.7M	2023-12-31	2026-02-24	10-K	26-065194
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$60.9M	2022-12-31	2025-02-25	10-K	25-026076
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14.9M	2025-12-31	2026-02-24	10-K	26-065194
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$347.2M	2024-12-31	2026-02-24	10-K	26-065194
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.9M	2024-12-31	2026-02-24	10-K	26-065194
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$149.2M	2023-12-31	2026-02-24	10-K	26-065194
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33.7M	2023-12-31	2026-02-24	10-K	26-065194
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$22.5M	2022-12-31	2025-02-25	10-K	25-026076
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$49.0M	2022-12-31	2025-02-25	10-K	25-026076
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$22.3M	2025-12-31	2026-02-24	10-K	26-065194
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$80.0M	2025-12-31	2026-02-24	10-K	26-065194
24	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-02-24	10-K	26-065194
25	current assets	us-gaap:AssetsCurrent	$878.1M	2024-12-31	2026-02-24	10-K	26-065194

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	current liabilities	us-gaap:LiabilitiesCurrent	$182.1M	2024-12-31	2026-02-24	10-K	26-065194
27	assets	us-gaap:Assets	$1.5B	2023-12-31	2025-02-25	10-K	25-026076
28	assets	us-gaap:Assets	$1.3B	2022-12-31	2024-02-27	10-K	24-020622
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	101,856,245	2026-02-17	2026-02-24	10-K	26-065194
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,688,295	2025-02-18	2025-02-25	10-K	25-026076

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.